Browsing Category
Pharma Industry News
4729 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Madrigal Pharmaceuticals adds Phase 2 DGAT-2 inhibitor ervogastat to MASH pipeline under global licensing agreement
Find out how Madrigal Pharmaceuticals is expanding its MASH strategy with a global license for ervogastat, a Phase 2 DGAT-2 inhibitor.
How NVIDIA is embedding BioNeMo into life sciences R&D as AI-driven drug discovery scales commercially
Find out how NVIDIA is embedding BioNeMo into life sciences R&D as AI-driven drug discovery scales commercially across enterprise research pipelines.
Peer-reviewed data highlight LEON’s FR-JET modular mixer as a solution for scalable high-concentration mRNA-LNP production
Find out how peer-reviewed data show LEON’s FR-JET modular mixer enabling scalable high-concentration mRNA-LNP manufacturing with strong in vivo performance.
Camurus resubmits Oclaiz for FDA review as subcutaneous acromegaly therapy eyes June 2026 decision
Camurus's Oclaiz is back in FDA review for acromegaly. Find out what the June 2026 decision could mean for U.S. access and endocrine market disruption.
AbbVie strengthens U.S. manufacturing strategy with Arizona facility deal, reinforcing long-term supply resilience
Find out how AbbVie’s Arizona manufacturing acquisition strengthens U.S. drug production and reinforces long-term supply resilience.
Can dual-targeting therapies redefine second-line colorectal cancer treatment in 2026?
Can dual-targeting therapies like amivantamab transform second-line colorectal cancer care? Explore what’s changing and who stands to win. Read the full story.
Johnson & Johnson colorectal cancer trial data reveal promising long-term efficacy of amivantamab-vmjw plus chemotherapy
Find out how Johnson & Johnson’s amivantamab‑vmjw plus chemotherapy shows durable response in metastatic colorectal cancer and what this means for future therapy.
Foresee Pharmaceuticals licenses MMP-12 pipeline to Primevera in $594m reset to double down on CAMCEVI and injectables
Foresee signs $594 million licensing deal with Primevera Therapeutics to exit MMP-12 R&D and focus on CAMCEVI injectables. Read what this signals for biotech strategy.
How Polyrizon’s NASARIX branding strengthens PL-14’s positioning in non-drug allergy prevention
Find out how Polyrizon’s NASARIX branding move positions its PL-14 allergy blocker for regulatory progress and future commercialization.
Biofrontera reaches key clinical milestone with database locks across two ongoing studies
Find out why Biofrontera Inc.’s database locks for two clinical studies strengthen regulatory readiness and advance key data milestones.